Cell No. : Cell Name RCB1702 : SLVL  update : 2023/01/05
Comment			Human cell line derived from splenic B cell lymphoma.
Comment from the depositor
Terms and conditions			There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form			Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Depositor	Inokuchi, Koiti
		Originator	Inokuchi, Koiti
		Year of deposit	2000
		Another name	VL51
		Animal	_human < Mammals
		Genus	Homo
		Species	sapiens
		Race	Japanese
		Gender	Female
		Age at sampling	70 years
		Tissue	spleen
		Disease name	spleuic lymphoma
		Classification	cancer
		Lifespan	infinite
		Morphology	lymphocyte-like
		Cellosaurus(Expasy)	CVCL_3169
			deposit info	lot info
		Medium	Medium List
		Culture type		Suspension cells
		Culture medium		RPMI1640 + 10% FBS
		Antibiotics		Free
		Passage method		dilution
	Culture information	Passage ratio		1 : 4 split
		SC frequency		Subculture : 1-2 times/week, Medium Renewal : 2 times/week
		Temperature		37 ℃
		CO2 concentration		5 %
		Freeze medium		Medium + 10% DMSO
		Freezing method		Slow freezing
		Mycoplasma		(-)
		Animal PCR		OK
		Virus (HIV)		LT 400
		Virus (HTLV-1)		(-)
		Isozyme		LD, NP
		Chromosome mode		75-82(50) : /77(3),78(10),79(7),80(11),81(11),82(6)
		STR(human)		OK
Reference information		Reference	1
		User's Publication	5

Top

Reference

3139  Inokuchi K, Abo J, Takahashi H, Miyake K, Inokuchi S, Dan K, Nomura T  Establishment and characterization of a villous lymphoma cell line from splenic B-cell lymphoma.  Leuk Res  1995  19:817-22  PubMed ID: 8551798   DOI: 10.1016/0145-2126(95)00059-3

Top

User's Publication

16945  Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, Tamaru JI, Mukasa A, Matsuoka M, Komohara Y.  Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy  Cancer Sci  2022  113(6):2129-2143  PubMed ID: 35343027   DOI: 10.1111/cas.15349

11433  Chiu H, Trisal P, Bjorklund C, Carrancio S, Toraño EG, Guarinos C, Papazoglou D, Hagner PR, Beldi-Ferchiou A, Tarte K, Delfau-Larue MH, Morschhauser F, Ramsay AG, Gandhi AK.  Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.  Br. J. Haematol.  2019    PubMed ID: 30767211   DOI: 10.1111/bjh.15797

10269  Komohara Y, Ma C, Yano H, Pan C, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Okuno Y, Nosaka K, Shimosaki S, Morishita K, Matsuoka M, Wakayama T, Takeya M.  Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages  J Clin Exp Hematop  2017  57:15-20  PubMed ID: 28420814   DOI: 10.3960/jslrt.17003

13994  Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y.  An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma  Cancer Sci  2016  107(11):1696-1704  PubMed ID: 27564404   DOI: 10.1111/cas.13065

15339  Bai B, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Takeya M, Komohara Y.  Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: the in vitro study  J Clin Exp Hematop  2013  53(2):127-33  PubMed ID: 23995109   DOI: 10.3960/jslrt.53.127